Prevention of Lower Urinary Tract Systems (PLUS) Research Consortium Clinical Research Centers (U01 Clinical Trial Optional)
The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. This FOA is to invite applications for Clinical Research Centers to build on foundational work to establish a longitudinal cohort study with the intent of identifying plausible targets for future intervention studies. The consortium will also conduct a range of additional studies to facilitate the success of future intervention and implementation studies.
Funding Agency: NIH
Deadline: November 7, 2019
Amount: $450,000
For more information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-015.html
Prevention of Lower Urinary Tract Systems (PLUS) Research Consortium Clinical Research Centers (U24 Clinical Trial Optional)
The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Scientific and Data Center to build on foundational work to establish a longitudinal cohort study with the intent of identifying plausible targets for future intervention studies. The consortium will also conduct a range of additional studies to facilitate the success of future intervention and implementation studies.
Funding Agency: NIH
Deadline: November 7, 2019
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-016.html
Revision Applications for Mechanisms of Drug Resistance (U54 Clinical Trials Not Allowed)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to currently funded NCI Specialized Center–Cooperative Agreements that will inform on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.
Funding Agency: NIH
Deadline: June 23, 2021
Amount: $250,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-051.html
Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing. This initiative will support secondary data analyses using archived HIV/AIDS data and specimens to generate new research questions and findings relevant to the scientific mission and priorities of the NICHD, Maternal and Pediatric Infectious Disease Branch(MPIDB) and Office of AIDS Research (OAR). The goal of this initiative is to continue the encouragement of the scientific community to utilize HIV/AIDS archived data sets and specimen collections to answer important questions about the epidemiology, pathogenesis, treatment, clinical manifestations and complications of HIV/AIDS in maternal, pediatric and adolescent populations.
Funding Agency: NIH
Deadline: November 1, 2019
Amount: $200,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-20-020.html
Catalyze: Product Definition for Small Molecules and Biologics – Preliminary Product/Lead Series Identification (R33 – Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.
Funding Agency: NIH
Deadline: August 11, 2021
Amount: $350,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-027.html
Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 – Clinical Trials Not Allowed)
This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.
Funding Agency: NIH
Deadline: August 11, 2021
Amount: $250,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-028.html
Enabling Technologies and Transformative Platforms for HLBS Research (R33 – Clinical Trials Not Allowed)
This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This FOA is part of a suite of NHLBI Catalyze program to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.
Funding Agency: NIH
Deadline: August 11, 2021
Amount: $300,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-022.html
Stimulating Access to Research in Residency Transition Scholar (stARRTS) (K38) (Clinical Trial Not Allowed)
The purpose of this program is to provide continued support to Transition Scholars who have successfully matriculated through the NIH Stimulating Access to Research in Residency (StARR) R38 program as resident investigators, and who demonstrate potential and continued interest in pursuing careers as clinician-investigators. Awards will provide 12-24 months of mentored research and career development support to those individuals who completed R38 research training, have secured a clinical fellowship or early-career faculty appointment (as instructor or assistant professor for less than 40 months at the time of submission or resubmission), and propose a strong research and career development plan towards continued, successful research careers.
Funding Agency: NIH
Deadline: January 14, 2022
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-006.html
Catalyze: Product Definition for Small Molecules and Biologics – Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.
Funding Agency: NIH
Deadline: August 11, 2021
Amount: $350,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-023.html
State and Regional Primary Care Association (PCA) Cooperative Agreements
This notice announces the opportunity to apply for State and Regional Primary Care Association (PCA) Cooperative Agreements funding to provide training and technical assistance (T/TA) to existing and potential Health Center Program award recipients and look-alikes1 (hereafter referred to as health centers). The Health Resources and Services Administration (HRSA) seeks to fund up to 52 organizations to provide T/TA to support health centers to provide comprehensive, high quality primary health care and improve the health of individuals and communities, through the following goals: Increase access to comprehensive primary care; Accelerate value-based care delivery; Foster a workforce to address current and emerging needs; Enhance emergency preparedness and response; and Advance clinical quality and performance.
Funding Agency: Health Resources and Services Administration
Deadline: November 8, 2019
For more information: Go to grants.gov and search opportunity #HRSA-20-021
Maximizing Investigators’ Research Award (R35 – Clinical Trial Optional)
The Maximizing Investigators’ Research Award (MIRA) provides support for the program of research in an investigator’s laboratory that is within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; More widely distribute funding among the nation’s highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. This FOA allows both new applications from eligible NIGMS-funded investigators and renewal applications from current established and early-stage MIRA grantees.
Funding Agency: NIH
Deadline: May 17, 2022
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-367.html
Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.
Funding Agency: NIH
Deadline: September 7, 2021
Amount: $499,999
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-368.html
NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)
The purpose of the NIAID Career Transition Award (CTA) program is to assist postdoctoral fellows’ transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Funding Agency: NIH
Deadline: January 7, 2022
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-371.html
Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC will be considered not responsive to this FOA and will not be accepted.
Funding Agency: NIH
Deadline: May 7, 2021
Amount: $200,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-369.html
Institutional Research and Academic Career Development Awards (IRACDA) (K12 – Independent Clinical Trial Not Allowed)
The purpose of the Institutional Research and Academic Career Development Award (IRACDA) Program is to develop a diverse pool of well-trained scientists available to address the nation’s biomedical research agenda. The program requires effective partnerships between a research-intensive institution and a teaching-intensive partner institution that has a historical mission or a demonstrated commitment to educating students from groups underrepresented in the biomedical research workforce. The IRACDA program provides support for a mentored postdoctoral research training experience at the research-intensive institution and funding for the IRACDA scholars to develop critical teaching and mentoring skills at a partner institution. The primary goals of the IRACDA program are to develop a diverse pool of well-trained biomedical scientists who have the necessary knowledge and skills to pursue independent academic careers and to enhance science educational offerings at partner institutions. This Funding Opportunity Announcement (FOA) does not allow appointed scholars to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.
Funding Agency: NIH
Deadline: October 1, 2021
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-366.html
NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)
The NIDCR Small Grant Program for New Investigators (R03) supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator initiated Research Project Grant (R01) or equivalent application.
Funding Agency: NIH
Deadline: September 7, 2022
Amount: $100,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-370.html
Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and health disparity populations.
Funding Agency: NIH
Deadline: November 8, 2022
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-372.html
Scholarly Editions and Scholarly Translations
The National Endowment for the Humanities (NEH) Division of Research Programs is currently accepting applications for its Scholarly Editions and Scholarly Translations program. This program supports the preparation of editions and translations of pre-existing texts that are foundational to humanities learning and research, but are currently inaccessible to the larger scholarly community and general audiences, or available only in inadequate editions or translations. Typically, the texts are significant literary, philosophical, and historical materials, but other types of work, such as musical notation, may also be included.
Funding Agency: NEH
Deadline: December 4, 2019
Amount: $525,000
For more information: https://www.neh.gov/grants/research/scholarly-editions-and-translations-grants
Tailoring Interventions to Improve Preventive Health Service Use (R61/R33 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) invites R61/12/R33 applications to develop interventions for physician compliance with recommended prevention guidelines for the elderly from the Centers for Disease Control and Prevention (CDC) and the US Preventive Services Task Force (USPTF). Specifically, applicants will develop electronic health record (EHR)-based interventions to improve the quality of care and health outcomes, and reduce health disparities. This FOA will support an R261 pilot phase, which will allow researchers to use data analytics tools, including machine learning approaches, to establish the feasibility of identifying groups of patients not receiving recommended preventive care, and then create scalable, tailored interventions for these groups to help overcome barriers to uptake. If successful, researchers may transition to an R33 phase for implementation of pragmatic trials. All applicants are required to address health disparities.
Funding Agency: NIH
Deadline: October 28, 2019
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-045.html
Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not-Allowed)
The Office of Research Infrastructure Programs (ORIP) encourages grant applications aimed at developing, characterizing or improving animal models of human diseases; improving access to information about or generated from the use of animal models of human disease; or improving diagnosis and control of diseases of laboratory animals. The animal models and related materials developed must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIPs trans-NIH mission. Applications must describe the need and potential impact of the proposed resources on broad research areas supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select area of research will not be considered acceptable. Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other Institutes and Centers will also not be acceptable for this FOA.
Funding Agency: NIH
Deadline: September 8, 2022
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-027.html
Advancing Sustained/Extended Release for HIV Prevention (A-SER) (R01 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release (SER) drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA focuses on the following scientific priority DDS: low-volume, self-injectable depots, erosible/biodegradable implants including in situ forming implants, intrauterine delivery systems and transdermal delivery systems. Applications will require an industry partner. Applications incorporating drugs that are already under development or approved for HIV prevention and/or treatment by their intellectual property/patent/license holder must involve these persons/entities in a meaningful and significant manner in the application through letters of support and/or other evidence of a substantial commitment.
Funding Agency: NIH
Deadline: December 4, 2019
Amount: $600,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-063.html
Smallsat Technology Partnerships
The Small Spacecraft Technology program within the NASA Space Technology Mission Directorate (STMD) is chartered to enable mission capabilities that are more rapid, more transformative, and more affordable than previously achievable. The Small Spacecraft Technology program seeks development projects and demonstration missions that are small, affordable, rapid, and transformative. All efforts will focus on small spacecraft capabilities that are relevant to NASA’s missions in science and exploration, including those with crosscutting applications to the needs of the broader small spacecraft community in industry, academia, and other government agencies. The goals of this appendix include collaboration with university teams that have experience in small spacecraft development and also extension of support to colleges and universities that have little or no previous involvement in this field. Colleges and universities with experience in small spacecraft development are encouraged to team with other college and universities to address these dual goals.
Funding Agency: NASA Headquarters
Deadline: November 6, 2019
Amount: $400,000
For more information: https://nspires.nasaprs.com/external/solicitations/summary!init.do?solId=%7B1CC0D04C-2870-B7CB-4661-1E3D8B546EA2%7D
Head Start and/or Early Head State Grantee – The City of Newark and Essex County, New Jersey
Through this announcement, the Administration for Children and Families solicits applications from public or private non-profit organizations, including community-based and faith-based organizations, or for-profit organizations that wish to compete for funds that are available to provide Head Start and/or Early Head Start services to children and families residing in the City of Newark and Essex County, New Jersey. Funds in the amount of $7,576,469 annually will be available to provide Head Start and/or Early Head Start program services to eligible children and their families. Interested applicants may email the OHS Operations Center at OHSTech@reviewops.org for additional information.
Funding Agency: Administration for Children and Families – OHS
Deadline: November 12, 2019
Amount: $7,576,469
For more information: https://ami.grantsolutions.gov/HHS-2020-ACF-OHS-CH-R02-1644
NIDDK Cooperative Centers of Excellence in Hematology (U54 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement is to invite U54 cooperative agreement applications for Cooperative Centers of Excellence in Hematology (CCEH). The NIDDK Hematology Centers Program is designed to increase access to critical research resources and collaboration in the national multidisciplinary research effort to combat nonmalignant hematologic diseases and to study normal hematopoiesis. In addition, it aims to improve cost-effectiveness of preparing critical reagents, maintaining state-of-the-art resources, and running multi-step molecular biologic assays. Each CCEH will support a minimum of three Biomedical Research Cores, an Administrative Core, and an Enrichment Program. The CCEH are expected to work collaboratively with the NIDDK Hematology Central Coordinating Center — together comprising the NIDDK Hematology Centers Program. By providing state-of-the-art equipment, resources, and expertise to the greater nonmalignant hematology research community, the program will serve as a national hub for nonmalignant hematology research, supporting career development of scientists just beginning their careers in the field and attracting established investigators from other domains. Funded Centers will cooperate with the NIDDK to facilitate research collaborations and interactions within and among Centers and with the wider research community.
Funding Agency: NIH
Deadline: June 30, 2020
Amount: $650,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-005.html
Data Sharing for Demographic Research Infrastructure Program (R24 Clinical Trial Not Allowed)
The purpose of this funding opportunity announcement (FOA) is to increase the impact of NICHD-funded research within the scientific mission of the NICHD Population Dynamics Branch (PDB) by providing research infrastructure to: promote data sharing; support the development of procedures and technologies for data sharing; disseminate best practices in data sharing; provide a resource that catalogs NICHD-funded data available for secondary analysis; and promote the secondary analysis of data collected through NICHD grants to research teams outside the original grantees.
Funding Agency: NIH
Deadline: November 29, 2019
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-20-001.html
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.
Funding Agency: NIH
Deadline: January 7, 2023
Amount: $200,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-375.html
Improving the Reach and Quality of Cancer Care in Rural Populations (R01 Clinical Trial Required)
The purpose of this Funding Opportunity Announcement (FOA) is to reduce the burden of cancer and improve the quality of cancer care in rural areas among low-income and/or underserved populations. The FOA encourages two types of applications: 1) observational research that includes pilot testing of intervention to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or 2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations. Specifically, the focus for observational studies (with pilot testing) is understanding and addressing the predictive and/or mediating role of social determinants of health, barriers to care, and treatment; and the focus for interventional research is on addressing quality of care related to cancer diagnosis, treatment and/or survivorship. Most existing cancer control interventions are not ready for direct implementation and dissemination in low-income rural areas, so proposals should seek to develop, adapt, and/or implement, and test interventions.
Funding Agency: NIH
Deadline: January 15, 2020
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-064.html
Fertility and Fertility Preservation for Patients with Diseases that Previously Precluded Reproduction (R21 Clinical Trial Optional)
The purpose of this RFA is to encourage studies on reproductive health, fertility and fertility preservation/treatment options in patients born with a serious chronic condition who can now expect to survive into adulthood healthy enough to consider their reproductive health and fertility options. The underlying pathophysiology of diseases such as sickle cell anemia, thalassemia, and cystic fibrosis, among others, and/or the cumulative effects of their treatment, can compromise reproductive health. This RFA encourages teams of scientists with expertise in the realm of the particular disease and in reproductive health and fertility to work together to understand the effects of the diseases and/or their treatments on parameters of reproductive health, and to identify ways to preserve, protect, or treat and reproductive deficits in these patients.
Funding Agency: NIH
Deadline: November 26, 2019
Amount: $200,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-20-021.html
AmeriCorps State and National Grants FY2020
AmeriCorps grants are awarded to eligible organizations proposing to engage AmeriCorps members in evidence-based or evidence-informed interventions to strengthen communities. An AmeriCorps member is an individual who engages in community service through an approved national service position. Members may receive a living allowance and other benefits while serving. Upon successful completion of their service, members earn a Segal AmeriCorps Education Award from the National Service Trust that members can use to pay for higher education expenses or apply to qualified student loans.
Funding Agency: Corporation for National and Community Service
Deadline: January 8, 2020
For more information: https://nationalservice.gov/build-your-capacity/grants/funding-opportunities/2020/americorps-state-and-national-grants-fy-2020
MD-PhD Training Program in Alzheimer’s Disease and Related Dementias and the Behavioral and Social Sciences (T32 Clinical Trial Not Allowed)
NIA’s MD-PhD Training Program in Alzheimer’s Disease and Its Related Dementias and the Behavioral and Social Sciences is designed to help strengthen the pipeline of physician-scientist leaders dedicated to using social and behavioral science approaches to addressing the nation’s challenges posed by Alzheimer’s disease and its related dementias (AD/ADRD). This FOA provides support to eligible domestic institutions to develop and implement effective approaches to integrated dual-degree training leading to the award of both an MD and a research doctorate degree (PhD or equivalent, e.g. DSW).
Funding Agency: NIH
Deadline: October 28, 2019
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-032.html
The Rat Opioid Genome Project: Clinical Trials not Allowed (U01 – Clinical Trial Not Allowed)
There are two main purposes of the Rat Opioid Genome Project. The first is to tease out genetic, genomic, and molecular (epi)genetic variants that underlie phenotypes associated with distinct stages along the opioid use disorder (OUD) trajectory to identify potential targets for future interventions at early stages along the trajectory. The second is to identify genetic, genomic, and molecular (epi)genetic variants underlying comorbid conditions and/or phenotypes that can be used to develop therapeutics to save lives of people who are at the end stages of the OUD trajectory.
Funding Agency: NIH
Deadline: November 19, 2019
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-010.html